Hillstream Biopharma (NASDAQ:CNTN) Posts Quarterly Earnings Results

Hillstream Biopharma (NASDAQ:CNTN) issued its quarterly earnings results on Friday. The company reported ($0.08) EPS for the quarter, FiscalAI reports.

Hillstream Biopharma Trading Up 2.3%

CNTN traded up $0.04 during trading on Friday, reaching $2.02. The stock had a trading volume of 603,628 shares, compared to its average volume of 844,799. The firm’s 50-day moving average is $2.47. Hillstream Biopharma has a one year low of $1.08 and a one year high of $9.08. The stock has a market capitalization of $155.40 million, a PE ratio of -1.75 and a beta of 1.45.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Hillstream Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, July 12th. Weiss Ratings downgraded Hillstream Biopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, July 15th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Insider Buying and Selling at Hillstream Biopharma

In other Hillstream Biopharma news, Director Gary S. Stetz sold 87,851 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $3.42, for a total value of $300,450.42. Following the completion of the sale, the director owned 146,675 shares of the company’s stock, valued at $501,628.50. This represents a 37.46% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.34% of the company’s stock.

About Hillstream Biopharma

Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company’s product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells.